ONGLYZA

Product Overview

About ONGLYZA

ONGLYZA is a medication containing the active ingredient Saxagliptin, classified as Sodium-Glucose Cotransporter 2 Inhibitor. Saxagliptin, sold under the brand name Onglyza, is an oral hypoglycemic of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug.

Key Benefits & Uses

• Used for: 1 INDICATIONS AND USAGE Dapagliflozin and saxagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults.
• Use only as directed on the product label or by a healthcare professional.
• Follow the authorised product information for dosing and duration of use.

Active Ingredient & Action

Saxagliptin, the active ingredient in ONGLYZA, belongs to the Sodium-Glucose Cotransporter 2 Inhibitor class. 1 INDICATIONS AND USAGE Dapagliflozin and saxagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Inactive ingredients: not listed in source data.

Important Notes

Always read and follow the label instructions carefully before taking ONGLYZA. If you have any underlying medical conditions, are taking other medicines, or are pregnant or breastfeeding, consult a doctor or pharmacist before use. Do not exceed the recommended dose on the package and do not use ONGLYZA for extended periods without medical advice.